Canaccord raised the firm’s price target on Globus Medical (GMED) to $92 from $85 and keeps a Buy rating on the shares. The firm updated its model and rolled its valuation methodology forward.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical assumed at Overweight from Equal Weight at Morgan Stanley
- Globus Medical launches ExcelsiusHub navigation system
- Globus Medical price target raised to $83 from $74 at Morgan Stanley
- Globus Medical price target raised to $92 from $80 at Stifel
- Morning Movers: CVS Health surges and ODP sinks following Q3 results
Questions or Comments about the article? Write to editor@tipranks.com